Articles by master

Saiba Animal Health AG today announced the publication of proof of principle data for a vaccine with the potential to translate into a novel therapy for osteoarthritic pain in companion animals

Zürich Switzerland 19th of March 2019 – Saiba Animal Health AG today announced the publication of proof of principle data for a vaccine with the potential to translate into a novel therapy for osteoarthritic pain in companion animals. The data were published online 12th of March 2019 in an article entitled “Active immunisation targeting nerve …

Read More

Saiba Animal Health to present at Animal Health Investment Forum London

Saiba Animal Health AG today announced that it has been selected as a finalist to present at the prestigious Animal Health Investment Europe Forum in February 2019. The Animal Health Innovation showcase provides an opportunity for the most exciting and innovative emerging animal health companies, selected by committee, to present their breakthrough innovations and business …

Read More

Proof of concept data for Saiba Animal Health’s virus-like particle vaccine for treating canine atopic dermatitis published in leading allergy journal

Zürich Switzerland 11th of April 2018 – Saiba Animal Health AG today announced the publication of Proof of Concept data for a vaccine for treating canine atopic dermatitis (CAD) in the renowned Journal of Allergy and Clinical Immunology. The data were published online 4th of April 2018 in an article entitled “Vaccination against IL‐31 for …

Read More

Saiba Animal Health and HypoPet merge into a single entity

In May 2017 Saiba Animal Health GmbH and HypoPet AG announced a merger into a single company now known as Saiba Animal Health AG with its headquarters in Pfäffikon SZ Switzerland. The merger of the two sister companies brings their lead projects, the HypoCat Fel d 1 vaccine and a canine atopic dermatitis vaccine, both …

Read More

Benchmark secures licensing deal for state-of-the-art Canine Atopic Dermatitis vaccine

Benchmark has secured an exclusive worldwide license from Saiba Animal Health GmbH, to develop and commercialise a recombinant vaccine for Canine Atopic Dermatitis (CAD) using Virus Like-Particle (VLP) technology. Link to full release from Benchmark

Read More

Benchmark Holdings PLC announces an agreement with Saiba Animal Health AG for HypoCat

Benchmark Holdings PLC, the international animal health, technical publishing and sustainability science business, announces that its Animal Health division has entered into an agreement with Saiba Animal Health AG (“Saiba Animal Health”). With an estimated 10% of the global population suffering from cat allergies, the agreement between Saiba Animal Health and Benchmark is designed to …

Read More
1 2 3 4